Welcome to the HBOT News Network

Hyperbaric Oxygen Therapy (HBOT) is increasingly appearing in the news and new research as a treatment for a variety of conditions involving inflammation.  Use the search or select an article below to keep up to date on the most recent HBOT News.

Recent Hyperbaric Oxygen Therapy (HBOT) News

Recent Hyperbaric Oxygen Therapy (HBOT) Research

Clinical Trial – Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)

The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic.So far, no
specific treatment has proven efficacy. Recent case series reported the use of Hyperbaric
Oxygen Therapy (HBOT) on 5 severe COVID-19 patients who developed respiratory insufficiency.
HBOT mechanisms of tissue oxygenation and anti-inflammatory effect may explain these
findings.

The purpose of the current study is the evaluate the efficacy of HBOT in moderate-severe
COVID-19 patients in a randomized controlled manner.

Clinical Trial – Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)

Several patients with hypoxaemic SARS-CoV2 pneumonia were able to benefit from hyperbaric oxygen treatment (HBOT) in China. In a clinical case published in the Chinese journal of hyperbaric medicine, treatment with repeated HBO sessions prevented admission to intensive care unit with mechanical ventilation in a patient aged 69 who presented with signs of respiratory decompensation. HBOT is the most powerful oxygenation modality in the body today. HBOT can dramatically increase the amount of dissolved oxygen in the blood. HBOT not only promotes blood transport but also its tissue delivery. Furthermore, HBOT has specific immunomodulatory properties, both humoral and cellular, making it possible, for example, to reduce the intensity of the inflammatory response and to stimulate antioxidant defenses by repeating sessions. A virucidal capacity of HBOT might also be involved. HBOT is generally regarded as safe with very few adverse events.